Coronary Stents Market Size, Share, Growth – By Product, By Type, By Material, By End Use, Global Forecast, 2025 to 2034

Coronary Stents Market Size

The global coronary stents market size was valued at USD 7.5 billion in 2024 and is expected to exhibit growth at a CAGR of 7.2% from 2025 to 2034. High market growth can be attributed to the rising prevalence of cardiovascular diseases, continuous advancements in stent technology, a growing geriatric population, and an increase in minimally invasive procedures, among other contributing factors.
 

Moreover, the rising prevalence of coronary artery disease (CAD), a primary cause of mortality globally, fuels the demand for coronary stents. For instance, according to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death worldwide, taking an estimated 17.9 million lives each year. Similarly, the Centers for Disease Control and Prevention (CDC) reports that approximately 18.2 million adults aged 20 and older in the U.S. have CAD. Factors such as inactive lifestyles, poor dietary habits, tobacco use, and aging populations contribute to the increase in cardiovascular disease cases, making stents an essential intervention for patients.
 

Furthermore, technological innovations, such as drug-eluting stents (DES), bioresorbable scaffolds, and polymer-free stents, improve patient outcomes by reducing the risks of restenosis and thrombosis. As these technologies continue to refine, patient and clinician confidence in stent efficacy grows, driving adoption.
 

Coronary stents are small, tube-like devices placed in narrowed or blocked coronary arteries to keep them open, improving blood flow to the heart. They are commonly used in patients with coronary artery disease to prevent heart attacks.
 

Coronary Stents Market Trends

The market is experiencing several trends that are shaping its growth and development. Factors such as the rising popularity of drug-eluting stents (DES), the growth of bioabsorbable and biodegradable stents, and the expansion of the revascularization patient pool, among others, are boosting industry growth.
 

• Bioabsorbable stents, which dissolve naturally over time, are gaining traction as they minimize long-term risks of stent thrombosis and reduce the need for prolonged antiplatelet therapy. Bioresorbable vascular scaffolds (BVS) offer a temporary support structure, dissolving after the artery heals, which is appealing in cases where long-term metal stents are not ideal.
   
• Moreover, as stent technology advances and clinical success rates improve, more patients, including those with complex artery lesions or co-morbidities, are becoming eligible for stent procedures. These advancements have expanded the market by making minimally invasive procedures possible for high-risk patients. Therefore, the aforementioned factors are expected to drive market growth.
   

Coronary Stents Market Analysis

Based on product, the market is classified into drug-eluting stent, bioresorbable vascular scaffold (BVS), and bare metal stent. The drug eluting stent segment generated the highest revenue of USD 6.4 billion in 2024.
 

• One of the main advantages of drug-eluting stents (DES) over bare-metal stents is their ability to significantly reduce restenosis (re-narrowing of the artery) by releasing medication that prevents excessive tissue growth. This leads to better long-term outcomes, making DES the preferred option in most coronary artery disease treatments.
   
• Moreover, DES has a lower rate of restenosis, meaning fewer follow-up interventions or repeat procedures are required compared to bare-metal stents. This lower recurrence rate is attractive to patients, healthcare providers, and insurers, as it reduces healthcare costs and improves patient outcomes.
   

Based on type, the coronary stents market is classified into balloon expendable stent and self-expendable stent. The balloon expendable stent segment dominated the market in 2024 with a market share of 58.3%.
 

• Balloon-expandable stents offer high precision during placement, allowing for accurate positioning and controlled deployment. This control minimizes the risk of damaging surrounding blood vessels and makes balloon-expandable stents an effective choice in complex or narrow artery cases where precise stent placement is essential.
   
• Additionally, balloon-expandable stents are particularly beneficial for patients with complex or calcified lesions. The ability to deploy stents at high pressure using balloon expansion is advantageous in treating hardened plaque or difficult arterial blockages, which would be challenging for other stent types. This is anticipated to boost the segment's growth in the market.
   

Based on material, the coronary stents market is segmented into cobalt-chromium alloy, stainless steel, and other materials. The cobalt-chromium alloy segment dominated the market in 2024 and is anticipated to reach USD 7.6 billion by the end of forecast period.
 

• Cobalt-chromium alloy is known for its high tensile strength and durability, making it ideal for withstanding the pressure of artery walls while maintaining lumen (inner diameter) expansion. This strength allows stents made of cobalt-chromium to remain durable over time, reducing the likelihood of fractures or failures and enhancing patient outcomes.
   
• Furthermore, the high strength of cobalt-chromium allows manufacturers to create stents with thinner struts without compromising structural integrity. Thin-strut designs reduce the risk of artery injury, improve blood flow, and promote faster healing. These key advantages help reduce restenosis (re-narrowing of arteries) and thrombosis risks, leading to segmental growth.
   

Based on end use, the coronary stents market is segmented into cardiac centers, hospitals, ambulatory surgical centers, and other end users. The cardiac centers segment dominated the market in 2024 and is anticipated to reach USD 6.9 billion by the end of forecast period.
 

• Cardiac centers are staffed with specialized cardiologists, interventional radiologists, and cardiac surgeons trained to perform complex procedures, such as stent placements and angioplasties. This level of expertise is vital for high-risk patients and complex cases, making cardiac centers a trusted choice for stent procedures.
   
• Additionally, these centers are equipped with advanced diagnostic and interventional technologies, such as intravascular ultrasound (IVUS), optical coherence tomography (OCT), and robotic-assisted systems. These technologies enhance procedural precision, allowing for accurate stent placement and reducing the risk of complications.

North America coronary stents market accounted for USD 3 billion market revenue in 2024 and is anticipated to grow at a CAGR of 6.4% between 2025 and 2034.
 

• North America, particularly the U.S., faces a significant burden of cardiovascular diseases, including coronary artery disease (CAD). Lifestyle factors such as sedentary behavior, high-fat diets, and stress contribute to a high incidence of CVDs, which, in turn, drives demand for coronary stent procedures to manage and treat these conditions.
   
• Further, the region boasts a well-developed healthcare system with state-of-the-art medical facilities, skilled healthcare providers, and easy access to advanced cardiac care. This robust infrastructure enables the widespread availability of coronary stent procedures and supports the adoption of innovative stent technologies across hospitals and cardiac centers, thereby driving regional growth.
   

Germany coronary stents market is projected to grow remarkably in the coming years.
 

• Germany is home to leading medical device companies and manufacturers of coronary stents, including BIOTRONIK, B. Braun, and other global players with strong regional operations. These companies contribute to innovation and market growth by producing high-quality, cutting-edge stent technologies.
   
• Moreover, the country’s comprehensive health insurance system covers most coronary procedures, including stent placements, reducing the financial burden on patients. Favorable reimbursement policies enable greater patient access to stent procedures, supporting consistent demand in the market.
   

China holds a dominant position in the Asia Pacific coronary stents market.
 

• China’s population is aging rapidly, with a growing proportion of elderly individuals who are more vulnerable to CVDs. The aging population is at higher risk of heart diseases, leading to increased demand for coronary stent procedures as part of the treatment for age-related cardiovascular conditions.
   
• The country is heavily investing in its healthcare infrastructure, including the development of advanced hospitals and medical centers in both urban and rural areas. As healthcare accessibility improves, the adoption of advanced technologies like coronary stents increases, especially in urban hospitals equipped with the latest medical technologies.
   

Coronary Stents Market Share

The market is characterized by the presence of several key global players, including Abbott Laboratories, Boston Scientific, Medtronic, and BIOTRONIK. These companies dominate the market with advanced product offerings such as drug-eluting stents, bioabsorbable stents, and cobalt-chromium alloy stents. The market is also seeing increasing competition from local manufacturers in emerging markets, which offer cost-effective solutions. Innovation, strategic partnerships, and mergers/acquisitions are central to the competition as companies aim to expand their product portfolios and geographic reach.
 

Coronary Stents Market Companies

Prominent players operating in the coronary stents industry include:

• Abbott Laboratories
• Andramed GmbH
• B. Braun Melsungen
• Biosensors International Group
• Biotronik SE & Co. KG
• Boston Scientific Corporation
• Cook Medical
• Elixir Medical Corporation
• GENOSS
• Medtronic
• Meril Life Science
• MicroPort Scientific Corporation
• Sahajanand Laser Technology
• Stryker Corporation
• Terumo Corporation
   

Coronary Stents Industry News:

• In May 2024, Abbott announced the launch of its XIENCE sierra everolimus-eluting coronary stent system in India. As one of the latest-generation stents in the XIENCE family, XIENCE sierra became available to patients with blocked coronary arteries. Designed for use in complex cases, the stent offers interventional cardiologists a high level of safety and reliability.
   
• In August 2022, Medtronic announced the launch of its latest drug-eluting coronary stent, the Onyx Frontier DES, following recent CE Mark approval. It introduced an advanced delivery system, enhancing upon the proven performance and clinical data of the Resolute Onyx DES. This stent leverages the same high-performing platform as the Resolute Onyx, with an optimized delivery system designed to improve ease of use and deliver superior acute performance, even in complex cases.
   

The coronary stents market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Drug-eluting stent
• Bioresorbable vascular scaffold (BVS)
• Bare metal stent

Market, By Type

• Balloon expendable stent
• Self-expendable stent

Market, By Material

• Cobalt-chromium alloy
• Stainless steel
• Other materials

Market, By End Use

• Cardiac centers
• Hospitals
• Ambulatory surgical centers
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE